Abstracts tagged "risk assessment"

Abstract Number: 0264 • ACR Convergence 2025
Seeing Beyond the Eye: Subclinical Audio-Vestibular Involvement in Vogt-Koyanagi-Harada Disease
Mohamed Tharwat Hegazy, Rania Yacoub, Sarah Sheta, Rana Hussein Amin and Noha Khalil, Faculty of Medicine, Cairo University, Cairo, Egypt
Background/Purpose: Vogt-Koyanagi-Harada disease (VKH) is a systemic disease that affects the central nervous system, ocular, and integumentary system. It causes bilateral granulomatous uveitis, dysacusia ranging…
Abstract Number: 2658 • ACR Convergence 2025
Risk of Immune-Mediated Inflammatory Diseases and Other Safety Outcomes in Patients with T2DM and Obesity Initiating GLP-1 RA: A Propensity Score-Matched Multi-center Study using the TriNetX Global Network
Hsin-Hua Chen and Wen-Cheng Chao, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes mellitus (T2DM) and obesity due to their beneficial metabolic effects. However,…
Abstract Number: 1975 • ACR Convergence 2025
Baseline QTc Screening and Monitoring Among SARD Patients with High Cardiovascular Risks on Hydroxychloroquine Based on 2021 ACR Consensus: A Quality Improvement Project
Cristine Kuzhuppilly Arcilla¹, Gabriel Kirsch², Gurjit Kaeley³ and Myint Thway⁴, ¹University of Florida Jacksonville, Jacksonville, FL, ²University of Florida - Jacksonville, Jacksonville, FL, ³UF COM-J, Ponte Vedra Beach, FL, ⁴UF Jacksonville, ponte vedra, FL
Background/Purpose: In 2017, FDA approved warnings regarding fatal cardiac effects such as cardiomyopathy, torsades de pointes, and QTc prolongation related to both acute and chronic…
Abstract Number: 1090 • ACR Convergence 2025
Quantitative Immunoglobulin Screening Prior to Rituximab Initiation: A Retrospective Cohort Study
Amelia Khoo and Anokhi Saklecha, Yale University, New Haven, CT
Background/Purpose: Rituximab, a monoclonal antibody which binds to the CD20 antigen of B cells, is used in the treatment of many rheumatologic conditions. Due to…
Abstract Number: 0230 • ACR Convergence 2025
An Epic journey – Therapeutic Drug Monitoring at an Academic Center
Puja Khanna¹ and Michael Rice², ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Gastroenterology, University of Michigan, Ann Arbor, MI
Background/Purpose: Non-oncologic use of immunomodulatory agents is increasing. These drugs have a narrow, patient-specific therapeutic index, making therapeutic drug monitoring essential for safe prescribing. However,…
Abstract Number: 2633 • ACR Convergence 2025
Comparative 3-year Safety Outcomes in Patients with Ankylosing Spondylitis Initiating JAK Inhibitor or TNF Inhibitor Therapy
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: To compare safety outcomes in patients with ankylosing spondylitis (AS) initiating Janus kinase inhibitors (JAKi) versus tumor necrosis factor inhibitors (TNFi).Methods: This retrospective cohort…
Abstract Number: 1953 • ACR Convergence 2025
Machine Learning-Based Classification of Raynaud’s Phenomenon and Autoimmune Diseases in Indeterminate Capillaroscopic Patterns
Genessis Maldonado¹, Adela Marin Ballve², Luis Sáez Comet³, Mayka Freire Dapena⁴, Miguel Antonio Mesa⁵, Miguel Martín Cascón⁶, Gema María Lledó Ibáñez⁷, Elena Martínez Robles⁸, Begoña Marí-Alfonso⁹, Alfredo Guillén del Castillo¹⁰, Carmen Pilar Simeón Aznar¹⁰, Borja del Carmelo Gracia Tello², Eduardo Ramos ibáñez¹¹ and Tracy Frech¹², ¹Vanderbilt University Medical Center, Nashville, ²Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ³Hospital Universitario Miguel Servet; Zaragoza, Zaragoza, Spain, ⁴Hospital Clínico Universitario de Santiago de Compostela, La Coruña, Spain, ⁵Universidad Pontificia Bolivariana, Medellin, Colombia, ⁶Hospital General Universitario Morales Meseguer, Murcia, Spain, ⁷Hospital Clínic de Barcelona, Barcelona, Spain, ⁸Hospital Universitario La Paz, Madrid, Spain, ⁹Hospital Universitario Parc Taulí, Barcelona, Spain, ¹⁰Hospital Universitario Vall D´Hebron, Barcelona, Spain, ¹¹Capillary.io, Zaragoza, Aragon, Spain, ¹²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Artificial intelligence (AI) has increasingly been integrated into the analysis of nailfold capillaroscopy (NFC), offering new opportunities to automate image interpretation and enhance diagnostic…
Abstract Number: 1070 • ACR Convergence 2025
Cervical Cancer and HPV Screening in Women with Lupus vs Healthy Control Group: A Retrospective Study at a Tertiary Referral Center
Mahnoor Javed¹, Deepak Jagannath², Alma Aveytia Camacho³, Alwyn Mathew³, Konrad Harms³, Soudabeh Daliri³ and Myriam Guevara⁴, ¹Houston Methodist, Richmond, TX, ²Houston Methodist Hospital, Sugar Land, TX, ³Houston Methodist, Houston, ⁴Houston Methodist, Houston, TX
Background/Purpose: Women with SLE are at an increased risk of developing cervical cancer, primarily by human papillomavirus (HPV) and immunosuppression. This elevated risk has been…
Abstract Number: 0213 • ACR Convergence 2025
Development of a Predictive Tool for Obstetric Risk Stratification in Autoimmune Rheumatic Diseases: A Meta-Analysis-Based Model
Noe Macias-Segura¹, Rodolfo Martinez-Canales¹, Braulio R. Avalos-Garcia², Andres M. Ortiz-Rios², Eva Abigaid Galindo-Calvillo², Mario Cesar Salinas-Carmona¹, Lorena Perez-Barbosa², Dionicio A. Galarza-Delgado³ and Cassandra Michele Skinner-Taylor², ¹Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Autoimmune rheumatic diseases (ARDs) such as systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), rheumatoid arthritis (RA), and Sjögren's syndrome significantly increase the risk of…
Abstract Number: 2568 • ACR Convergence 2025
Cardiovascular Risk Prediction in Systemic Lupus Erythematosus: Comparing the PREVENT and SLECRISK Models
Youngmin Kim¹, Hongshu Guan², Emily Oakes¹, Katherine Zhong³, Misti Paudel⁴, May Choi⁵, Katherine Liao¹, Brittany Weber⁶ and Karen H. Costenbader⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital/ Harvard Medical School, Boston, ³Brigham and Women's Hospital, Short Hills, NJ, ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵University of Calgary, Calgary, AB, Canada, ⁶Brigham and Women's Hospital, DEDHAM, MA, ⁷Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased risk for atherosclerotic cardiovascular disease (CVD) events, often underrepresented in traditional risk models. We previously developed…
Abstract Number: 1954 • ACR Convergence 2025
Revolutionizing Microvascular Screening: AI-Powered Dermatoscopy for Efficient Nailfold Capillary Evaluation
Genessis Maldonado¹, Eduardo Ramos ibáñez², Borja del Carmelo Gracia Tello³ and Tracy Frech⁴, ¹Vanderbilt University Medical Center, Nashville, ²Capillary.io, Zaragoza, Aragon, Spain, ³Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ⁴Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Nailfold capillaroscopy plays a critical role in the diagnosis and management of systemic sclerosis (SSc) and related connective tissue diseases. However, access to capillaroscopy…
Abstract Number: 1037 • ACR Convergence 2025
Risk Factor Identification and Dynamic Individualized Prediction of Muscle Involvement in Systemic Sclerosis
Zixing Liu¹, Adrianne Woods², Julie Paik², Laura Hummers², Scott Zeger¹, Ami Shah² and Ji Soo Kim³, ¹Johns Hopkins Biostatistics, Baltimore, MD, ²Johns Hopkins Rheumatology, Baltimore, MD, ³Johns Hopkins, Baltimore, MD
Background/Purpose: Myopathy in SSc significantly increases disability, reduces quality of life, and elevates mortality risk, yet remains understudied. Most identified risk factors derive from cross-sectional…
Abstract Number: 0212 • ACR Convergence 2025
Biomarker-Guided Therapeutic Calculator for Personalized Management in Pregnant Patients with Autoimmune Rheumatic Diseases
Noe Macias-Segura¹, Rodolfo Martinez-Canales¹, Andres M. Ortiz-Rios², Braulio R. Avalos-Garcia², Eva Abigaid Galindo-Calvillo², Mario Cesar Salinas-Carmona¹, Lorena Perez-Barbosa², Dionicio A. Galarza-Delgado³ and Cassandra Michele Skinner-Taylor², ¹Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Therapeutic decisions during pregnancy in women with autoimmune rheumatic diseases (ARDs) such as SLE, APS, RA, and Sjögren’s syndrome require a personalized approach due…
Abstract Number: 2520 • ACR Convergence 2025
Evolution in Risk Stratification for Renal Outcomes in ANCA-Associated Vasculitides Using Established Scores and Histopathological Criteria in a Large European Cohort
Stefan Krämer¹, Kristian Vogt², Martin Busch³, Tobias Schmitt⁴, Raoul Bergner⁵, Sebastian Mosberger⁵, Thomas Neumann⁶, Teresa Schreibing¹, Fabian Schumbrink¹ and Thomas Rauen², ¹Department of Internal Medicine II, RWTH University Hospital Aachen, Aachen, Germany, ²Department of Internal Medicine II, RWTH University Hospital AachenMedicine II, Aachen, Germany, ³Department of Internal Medicine III, University Hospital, Friedrich-Schiller University, Jena, Jena, Germany, ⁴University Hospital Jena, Friedrich-Schiller University, Department of Internal Medicine III, Jena, Germany, ⁵Department of Internal Medicine A, Nephrology and Rheumatology, Municipal Hospital Ludwigshafen, Ludwigshafen, Germany, ⁶Department of Rheumatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
Background/Purpose: Glomerulonephritis is a common and threatening manifestation in ANCA-associated vasculitis (AAV). To assess the risk of end-stage kidney disease (ESKD), various scores have been…
Abstract Number: 1948 • ACR Convergence 2025
Enhanced Prediction of Knee Osteoarthritis Progression through Deep Learning-Based Multimodal Data Fusion
Daniela Herrera¹, Ahmad Almhdie-Imjabbar², Hechmi Toumi³ and Eric Lespessailles⁴, ¹PRIMMO- University Hospital Center of Orleans, Olreans, France, ²University Hospital Center of Orleans, Orleans, France, ³PRIMMO- University Hospital Center of Orleans, Orleans, France, ⁴CHU Orléans, Orléans, France
Background/Purpose: Effective diagnosis and management of knee osteoarthritis (KOA) increasingly rely on integrating diverse data sources, including imaging and clinical information. The practice of combining…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].